Cargando…

Narrative review: the holy grail: update on pharmacotherapy for heart failure with preserved ejection fraction

Heart failure with preserved ejection fraction (HFpEF) is the presence of clinical signs and/or symptoms of heart failure with a left ventricular ejection fraction (LVEF) ≥50%. Risk factors associated with this disease include hypertension, hyperlipidemia, atrial fibrillation (AF), obesity, diabetes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paz, Pablo Alejandro, Mantilla, Barbara Daniela, Argueta, Erwin E., Mukherjee, Debabrata
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Review article on Heart Failure Update and Advances in 2021
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039660/ https://www.ncbi.nlm.nih.gov/pubmed/33850920 http://dx.doi.org/10.21037/atm-20-4602

Ejemplares similares

Updates in pharmacotherapy of heart failure with reduced ejection fraction
por: Espinoza, Clifton, et al.
Publicado: (2021)

Right Heart Phenotype in Heart Failure With Preserved Ejection Fraction
por: Guazzi, Marco, et al.
Publicado: (2021)

Narrative review of pharmacotherapy for transthyretin cardiac amyloid
por: Cruz Rodriguez, Jose B., et al.
Publicado: (2021)

Editorial for “Heart Failure Update and Advances in 2021”
por: Mukherjee, Debabrata, et al.
Publicado: (2021)

Heart Failure With Mid-range or Recovered Ejection Fraction: Differential Determinants of Transition
por: Margonato, Davide, et al.
Publicado: (2020)

Efficacy of Ranolazine to Improve Diastolic Performance in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-analysis
por: Putri, Desak Ketut Sekar Cempaka, et al.
Publicado: (2023)

Prognostic impacts of changes in left ventricular ejection fraction in heart failure patients with preserved left ventricular ejection fraction
por: Yoshihisa, Akiomi, et al.
Publicado: (2020)

Iron deficiency in heart failure with preserved ejection fraction: a systematic review and meta-analysis
por: Beale, Anna L, et al.
Publicado: (2019)

Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction
por: Salah, Khibar, et al.
Publicado: (2019)

Impact of atrial fibrillation in patients with heart failure and reduced, mid-range or preserved ejection fraction
por: Son, Mi Kyoung, et al.
Publicado: (2020)

Diastolic index as a short-term prognostic factor in heart failure with preserved ejection fraction
por: Hoshida, Shiro, et al.
Publicado: (2020)

Management of left ventricular thrombus: a narrative review
por: Cruz Rodriguez, Jose B., et al.
Publicado: (2021)

Reporting trends of randomised controlled trials in heart failure with preserved ejection fraction: a systematic review
por: Zheng, Sean L, et al.
Publicado: (2016)

Mild aortic valve disease and the diastolic pressure–volume relationship in heart failure with preserved ejection fraction
por: Verbrugge, Frederik H, et al.
Publicado: (2021)

Narrative review in the current role of angiotensin receptor-neprilysin inhibitors
por: Cruz Rodriguez, Jose B., et al.
Publicado: (2021)

Copeptin in patients with heart failure and preserved ejection fraction: a report from the prospective KaRen-study
por: Hage, Camilla, et al.
Publicado: (2015)

Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis
por: Zheng, Sean Lee, et al.
Publicado: (2018)

Baseline characteristics of patients with heart failure and preserved ejection fraction at admission with acute heart failure in Saudi Arabia
por: Abohammar, Samah, et al.
Publicado: (2017)

Development of algorithms for determining heart failure with reduced and preserved ejection fraction using nationwide electronic healthcare records in the UK
por: Sundaram, Varun, et al.
Publicado: (2022)

Medications for specific phenotypes of heart failure with preserved ejection fraction classified by a machine learning-based clustering model
por: Sotomi, Yohei, et al.
Publicado: (2023)

Developing a contemporary community clinic for patients with heart failure with preserved ejection fraction within the current National Health Service model
por: Tran, Patrick, et al.
Publicado: (2022)

Non-invasive intraventricular pressure differences estimated with cardiac MRI in subjects without heart failure and with heart failure with reduced and preserved ejection fraction
por: Londono-Hoyos, Francisco, et al.
Publicado: (2019)

Rationale and design of the preserved versus reduced ejection fraction biomarker registry and precision medicine database for ambulatory patients with heart failure (PREFER-HF) study
por: Abboud, Andrew, et al.
Publicado: (2021)

Colchicine in patients with heart failure and preserved left ventricular ejection fraction: rationale and design of a prospective, randomised, open-label, crossover clinical trial
por: Shchendrygina, Anastasia, et al.
Publicado: (2023)

Ischaemia change with revascularisation versus medical therapy in reduced ejection fraction
por: Mentz, Robert J, et al.
Publicado: (2015)

In Search of the Holy Grail: Stem Cell Therapy as a Novel Treatment of Heart Failure with Preserved Ejection Fraction
por: Domaszk, Olaf, et al.
Publicado: (2023)

Ethnic differences in the association of QRS duration with ejection fraction and outcome in heart failure
por: Gijsberts, Crystel M, et al.
Publicado: (2016)

Sacubitril/valsartan reduces cardiac decompensation in heart failure with preserved ejection fraction: a meta-analysis
por: Basile, Christian, et al.
Publicado: (2023)

Association of early versus delayed normalisation of left ventricular ejection fraction with mortality in ischemic cardiomyopathy
por: Schiffer, Walter B, et al.
Publicado: (2021)

Implantation of a vagus nerve stimulator for patients with heart failure with reduced ejection fraction: An educational video
por: Al Rameni, Dina, et al.
Publicado: (2022)

Characteristics and clinical outcomes of patients with acute heart failure with a supranormal left ventricular ejection fraction
por: van Essen, Bart J., et al.
Publicado: (2022)

Incremental value of mineralocorticoid receptor antagonists in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan
por: Benini, Annachiara, et al.
Publicado: (2022)

Association between implanted cardioverter-defibrillators and mortality for patients with left ventricular ejection fraction between 30% and 35%
por: Wasfy, Jason H, et al.
Publicado: (2023)

Heart Failure with Preserved Ejection Fraction—a Concise Review
por: Adamczak, Daria M., et al.
Publicado: (2020)

Does lateral approach preserve the right ventricular function after HeartMate 3 insertion?
por: Hayashi, Hideyuki, et al.
Publicado: (2023)

Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study
por: Ganesananthan, Sashiananthan, et al.
Publicado: (2020)

Stalking the 'Holy Grail'
por: Brady, Margret
Publicado: (2005)

The Holy Grail of Psychiatry
por: Nemeroff, Charles B.
Publicado: (2015)

Pulmonary vasodilator use in continuous-flow left ventricular assist device management
por: Pirlamarla, Preethi, et al.
Publicado: (2021)

Optimal diuretic strategies in heart failure
por: Suri, Sarabjeet S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dnfp86mfsnjb83qal6vqlsuuho